Bile test could spot bile duct cancer without needle biopsy
NCT ID NCT06416397
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if a protein test on bile fluid can accurately diagnose cholangiocarcinoma (bile duct cancer). Researchers will collect bile samples from 200 adults with bile duct narrowing during a routine scope procedure. They will compare the protein test results with standard tissue biopsy results to see if the bile test is a reliable alternative.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with bile duct stenosis who require ERCP or a radiological procedure for diagnostic purposes (histological samples) as part of their management
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient 18 years and older * Patients with bile duct stenosis who require endoscopy with retrograde papillary catheterization or a radiological procedure for diagnostic purposes (histological samples) as part of their management * Oral consent Exclusion Criteria: * Pregnant woman * Patient under legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Bordeaux
RECRUITINGPessac, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Burning away bile duct blockages: a new weapon against cholangiocarcinoma?
- Can a Three-Drug chemo cocktail before surgery stop biliary tract cancer from coming back?
- Can a targeted drug combo outsmart bile duct cancer?
- Cutting scans, keeping safety: a new streamlined approach to liver cancer treatment
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?